Results 171 to 180 of about 25,814 (203)

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study. [PDF]

Breast
Oliveira LJC, Rosa DD, Katz A, Assad-Suzuki D, Argolo D, Sanches SM, Testa L, Bines J, Kaliks RA, de Melo Gagliato D, Barroso-Sousa R, Corrêa TS, Shimada AK, Dos Anjos CH, Linck R, Megid TBC, Batista DN, Gomes DM, Cesca MG, Gaudêncio D, Moura LMA, Pereira de Araújo JA, Bonadio RC, Silva de Souza Z, Beal JR, Lopes MM, Sales LT, Parisi Marlière JLF, Mano MS.   +28 more
europepmc   +1 more source

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study. [PDF]

J Clin Med
Veccia A, D'Argento E, Morgillo F, Pizzutilo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Morabito A, Gariazzo E, Genova C, Chiari R, Cristofano A, Delconte A, Vattemi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Azzarello G, Verderame F, Mazzi C, Bencardino D, Dipasquale M, Scala A, Della Corte CM, Piscazzi D, Gilli M, Bria E, Caffo O, Gori S, Inno A.   +32 more
europepmc   +1 more source

Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. [PDF]

Cancers (Basel)
Martínez-Vila C, Teixido C, Martín R, Aya F, Sudhaman S, Budde GL, González-Navarro EA, Alos L, Castrejon N, Ortiz JB, Krainock M, Liu MC, Arance A.   +12 more
europepmc   +1 more source

Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. [PDF]

Front Immunol
Les I, de Haedo D, Martínez M, Ibáñez-Beroiz B, Moreno A, de Elejoste I, Campillo-Calatayud A, Pérez-Francisco I, Cabero M, Elejalde I, Arrazubi V.   +10 more
europepmc   +1 more source

Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. [PDF]

J Kidney Cancer VHL
Airò G, Guida A, Gili A, Signori A, Rebuzzi SE, Maruzzo M, Lai E, Pierantoni F, Bimbatti D, Basso U, Damassi A, Calabrò F, Cerbone L, Caserta C, Sirgiovanni G, Serafin D, Caffo O, Scagliarini S, Bracarda S, Buti S.   +19 more
europepmc   +1 more source

Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report. [PDF]

Drugs Context
Lancianese A, Maccaroni E, Zepponi L, Giampieri R, Berardi R.   +4 more
europepmc   +1 more source

[Prescribing medicines in primary care teams: the challenge of multidisciplinarity and patient safety]. [PDF]

Aten Primaria
Luzón-Oliver L, Astier-Peña MP.
europepmc   +1 more source

Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations. [PDF]

Future Oncol
Bianchini G, Fabi A, Guarneri V, Arpino G, De Laurentis M, Zambelli A, Zamagni C, Biganzoli L, Puglisi F, Santini D.   +9 more
europepmc   +1 more source

HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy. [PDF]

ESMO Open
Pesántez D, Brasó-Maristany F, Pascual T, Angelats L, Indacochea A, Cuatrecasas M, López S, Sanfeliu E, Fernández-Esparrach G, Notario L, Méndez I, Momblan D, Candia L, Macias I, Prat A, Sauri T.   +15 more
europepmc   +1 more source

Experiencia del uso de pembrolizumab como tratamiento de primera línea en pacientes con melanoma irresecable/metastásico tratados en los servicios de oncología médica de los hospitales Dr. Rafael Ángel Calderón Guardia, Dr. Maximiliano Peralta Jiménez, México y San Juan de Dios del 01 de enero del 2019 al 31 de diciembre del 2023

Olivier Chaves Duarte
openalex   +1 more source